Cancer Immunotherapeutic (PCI) Strategy in Triple Negative Breast Cancer Patients

NCT07300475 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Triple Negative Breast Cancer

Interventions

DRUG: Paclitaxel
DRUG: Carboplatin
DRUG: Pembrolizumab
DRUG: Doxorubicin
DRUG: Cyclophosphamide
BIOLOGICAL: Personalized cancer immunotherapeutic (PCI)
DRUG: AB248 (CD8-selective IL-2 mutein fusion protein)
OTHER: pVAC tools neoantigen prediction algorithm
DRUG: poly-ICLC

Sponsor

Washington University School of Medicine